Video Latest - ecancer

CDK 4/6 inhibitors: Management of side effects

Dr Alison Jones - The LOC, London, UK

15 Nov 2016

Multidisciplinary collaboration and data sharing among new generation of students promises a bright future

Prof Richard Schilsky - Chief Medical Officer, ASCO

11 Nov 2016

The importance of translational cancer research

Dr Nils Brünner - University of Copenhagen, Copenhagen, Denmark

11 Nov 2016

Biomarkers of sensitivity and resistance

Dr Joan Seoane - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

26 Oct 2016

Editor's ESMO 2016 roundup

Prof Gordon McVie - Editor in Chief, ecancer

24 Oct 2016

Abiraterone in patients with recurrent epithelial ovarian cancer

Dr Susanna Banerjee - The Royal Marsden, London, UK

24 Oct 2016

Fatigue in men with castration resistant prostate cancer treated with enzalutamide

Dr Simon Chowdhury - Guy's Hospital, London, UK

21 Oct 2016

PDL-1 assay concordance

Dr Jill Walker - AstraZeneca, UK

20 Oct 2016

First evidence of significant clinical activity of PD1 inhibition in metastatic prostate cancer

Dr Julie Graff - Knight Cancer Institute, Oregon Health & Science University, Portland, USA

17 Oct 2016

CDK4/6 inhibitors for metastatic breast cancer

Dr Giuseppe Curigliano - European Institute of Oncology, Milan, Italy

14 Oct 2016

TRAIL induced apoptosis for cancer stem cells

Prof Waleed Arafat - Alexandria Faculty of Medicine, Alexandria, Egypt

12 Oct 2016

Carcinoid syndrome

Dr Rachel Riechelmann - Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil

12 Oct 2016

Video